Sugi Predict

Sugi Predict / Compounds / SCHEMBL7182252

SCHEMBL7182252

SCHEMBL7182252

CCC(C)[PH](=O)c1ccccc1C(=O)c1c(Cl)cccc1OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TGM2 P21980 1/20 0.40
▸ RORC P51449 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ HPGD P15428 2/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ FABP4 P15090 1/20 0.36
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA7 P43166 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ CA14 Q9ULX7 1/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ XBP1 P17861 1/20 0.35
▸ CES2 O00748 1/20 0.35
▸ CES1 P23141 1/20 0.35
▸ AKR1C3 P42330 1/20 0.35
▸ AKR1C2 P52895 1/20 0.35
▸ LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7187930 0.92 CA12 (0.40) HPGDCA12CA1CA2CA7
SCHEMBL7181406 0.89 TAS1R3 (0.39) RORCHPGDRAB9AKMT2ACES2
SCHEMBL7175837 0.85 RORC (0.41) RORCLMNA
SCHEMBL7177666 0.81 L3MBTL1 (0.38) SMN1; SMN2RAB9AL3MBTL1KMT2AMEN1
SCHEMBL7180613 0.78 TGM2 (0.38) TGM2RORCSMN1; SMN2HPGDRAB9A
SCHEMBL7182745 0.78 ALDH1A1 (0.41) TGM2RORCSMN1; SMN2HPGDRAB9A
SCHEMBL7189502 0.78 KMT2A (0.34) HPGDL3MBTL1KMT2AMEN1MAPT
SCHEMBL8401099 0.75 CA12 (0.47) TGM2SMN1; SMN2RAB9ACA12CA1
SCHEMBL7189504 0.74 CTSS (0.39) RORCLMNA
SCHEMBL8899649 0.73 KMT2A (0.41) TGM2RORCSMN1; SMN2HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 TGM2 3583/4885RORC 1336/4885SMN1; SMN2 2939/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 TGM2 3431/4885RORC 1254/4885SMN1; SMN2 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.